Repare Therapeutics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
RPTX Nasdaq 2836 www.reparerx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Repare Therapeutics Inc.

Sector Update: Health Care Stocks Rise Wednesday Afternoon - Dec 24th, 2025 10:08 am
Update: Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment; Repare Shares Rise - Dec 24th, 2025 7:49 am
Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration - Dec 24th, 2025 5:00 am
Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc. - Nov 20th, 2025 3:25 pm
Repare Therapeutics Inc. (RPTX) Reports Break-Even Earnings for Q3 - Nov 14th, 2025 4:00 pm
Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc. - Nov 14th, 2025 2:44 pm
Here's Why Repare Therapeutics (NASDAQ:RPTX) Must Use Its Cash Wisely - Oct 30th, 2025 6:30 am
Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors - Oct 17th, 2025 5:30 am
Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Oct 13th, 2025 2:05 pm
Repare Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Aug 10th, 2025 6:06 am
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates - Aug 8th, 2025 6:10 am
Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results - Aug 8th, 2025 5:00 am
OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee - Aug 6th, 2025 5:00 am
Repare Therapeutics Jumps 15% After $10M Licensing Deal With Debiopharm - Jul 16th, 2025 7:30 pm
Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib - Jul 15th, 2025 2:05 pm
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results - May 13th, 2025 2:05 pm
Repare signs out-licensing deal with DCx Biotherapeutics - May 2nd, 2025 2:27 am
Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics - May 1st, 2025 5:00 am
Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025 - Apr 25th, 2025 11:00 am
Repare Therapeutics Announces Leadership Transitions - Mar 31st, 2025 2:39 pm